Naturally Occurring Mutations of SARS-CoV-2 Main Protease Confer Drug Resistance to Nirmatrelvir.

Hu Y, Lewandowski EM, Tan H, Zhang X, Morgan RT, Zhang X, Jacobs LMC, Butler SG, Gongora MV, Choy J, Deng X, Chen Y, Wang J. · 2023

Read Naturally Occurring Mutations of SARS-CoV-2 Main Protease Confer Drug Resistance to Nirmatrelvir. by Hu Y, Lewandowski EM, Tan H, Zhang X, Morgan RT, Zhang X, Jacobs LMC, Butler SG, Gongora MV, Choy J, Deng X, Chen Y, Wang J. (2023) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc10451032.txt.

Introduction

Hu and co-authors tested in 2023 how changes in a virus enzyme could defeat a key Covid drug. The drug, nirmatrelvir, blocks the main protease of SARS-CoV-2, a tool the virus uses to build itself. New variants raised fears that the drug might fail. The team built and checked 102 changed forms of the enzyme.

Twenty-two changes at five spots kept the enzyme strong yet shrugged off the drug. Hu mapped the shapes of six of these forms with X-ray methods. Live virus tests then proved the resistance in full virus. Some drug-proof forms grew more weakly, a small comfort. The team flags these spots for close watch in clinics.

Catalog record

CREATORHu Y, Lewandowski EM, Tan H, Zhang X, Morgan RT, Zhang X, Jacobs LMC, Butler SG, Gongora MV, Choy J, Deng X, Chen Y, Wang J.
YEAR2023
COLLECTIONPAPERS
FORMATTXT
FILE SIZE62 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC10451032

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Naturally Occurring Mutations of SARS-CoV-2 Main Protease Confer Drug Resistance to Nirmatrelvir By Yanmei Hu, Eric M Lewandowski, Haozhou Tan, Xiaoming Zhang, Ryan T Morgan, Xiujun Zhang, Lian M C Jacobs, Shane G Butler, Maura V Gongora, John Choy, Xufang Deng, Yu Chen Published in: ACS Central Science DOI: 10.1021/acscentsci.3c00538 ABSTRACT Abstract The SARS-CoV-2 main protease (Mpro) is the drug target of Pfizer’s oral drug nirmatrelvir. The emergence of SARS-CoV-2 variants with mutations in Mpro raised the alarm of potential drug resistance. To identify potential clinically relevant drug-resistant mutants, we systematically characterized 102 naturally occurring Mpro mutants located at 12 residues at the nirmatrelvir-binding site, among which 22 mutations in 5 residues, including S144M/F/A/G/Y, M165T, E166 V/G/A, H172Q/F, and Q192T/S/L/A/I/P/H/V/W/C/F, showed comparable enzymatic activity to the wild-type (kcat/Km < 10-fold change) while being resistant to nirmatrelvir (Ki > 10-fold increase). X-ray crystal structures were determined for six representative mutants with and/or without GC-376/nirmatrelvir. Using recombinant SARS-CoV-2 viruses generated from reverse genetics, we confirmed the drug resistance in the antiviral assay and showed that Mpro mutants with reduced enzymatic activity had attenuated viral replication. Overall, our study identified several drug-resistant hotspots in Mpro that warrant close monitoring for possible clinical evidence of nirmatrelvir resistance, some of which have already emerged in independent viral passage assays conducted by others. INTRODUCTION The ongoing COVID-19 pandemic highlights the urgent need for oral bioavailable antiviral drugs. Paxlovid combines the viral main protease (Mpro or 3CLpro) inhibitor nirmatrelvir and its metabolic enhancer ritonavir.1,2 Paxlovid was approved by the FDA in 2021 for the treatment of mild-to-moderate COVID-19 in adults and children 12 years old or older with a positive test and who are at high risk of progression to severe COVID-19. Mpro is a cysteine protease that mediates the cleavage of viral polyproteins during viral replication and is a high-profile antiviral drug target.3,4 In addition to nirmatrelvir, other Mpro inhibitors that advanced to the clinical stage include PF-07304814 (phosphate form of PF-00835231), S-217622, PBI-0451, EDP-235, and 13b.5 The recent emergence of variants of concern, particularly the Omicron variant, raises the concern of possible altered susceptibility to vaccines and antiviral drugs. Predicting drug resistance before it becomes dominant in clinics is vital in facilitating antiviral drug development to combat the pandemic. Several recent studies reported the discovery of nirmatrelvir-resistant Mpro mutants using the viral passage experiments and identified mutations in residues S144, E166, and A173 that directly affect nirmatrelvir inhibition, as well as other compensatory mutations at residues L50 and T21 that improve viral fitness but have minimal impact on inhibitor binding.6−9 Since SARS-CoV-2 continues to evolve with or without selection pressure,10 we took an independent and systematic approach to identify naturally occurring drug-resistant Mpro mutations by exploiting the SARS-CoV-2 polymorphisms deposited in the Global Initiative on Sharing Avian Influenza Data (GISAID) database. As the sequences in GISAID might contain mutations from noninfectious viruses, our goal is to identify Mpro drug-resistant mutations with comparable enzymatic activity as the wild-type (WT). It is known that mutations with a significant reduction of enzymatic activity generally lead to attenuated viral replication.11 For this, we focus on mutations with similar enzymatic activity as the wild-type (kcat/Km < 10-fold change) while being resistant to nirmatrelvir (Ki > 10-fold increase). kcat is the catalytic constant, Km is the Michaelis–Menten constant, and Ki is the inhibition constant. In total, we systematically characterized the enzymatic activity, thermal stability, and drug sensitivity of 102 purified Mpro mutants that are located within 6 Å of the nirmatrelvir-binding site. While the majority of the Mpro mutants showed a significant reduction of enzymatic activity (kcat/Km > 10-fold change compared to WT), we discovered 22 mutations in 5 residues that meet our criteria (kcat/Km < 10-fold change and Ki > 10-fold increase). The X-ray crystal structures of the representative Mpro mutants S144A, S144L, M165Y, E166Q, H172Y, and Q192T with and/or without GC-376/nirmatrelvir provide a structural explanation for the drug resistance. In addition, the viral growth kinetics and drug resistance were characterized using recombinant SARS-CoV-2 viruses with selected Mpro mutants. Taken together, this study identified several nirmatrelvir-resistant hotspots that warrant close monitoring while highlighting the future risk of mutants with multiple substitutions at these sites that can directly impart drug resistance, combined with other sites that may enhance viral fitness. RESULTS AND DISCUSSION Identification of SARS-CoV-2 Mpro Mutants from GISAID Sequence Analysis Recent sequence analysis of SARS-CoV-2 Mpro revealed multiple prevalent mutations including G15S, T21I, L89F, K90R, P108S, P132H, and L205V.12−14 All these mutants are located outside the nirmatrelvir-binding site (Figure 1a) and were found to have similar catalytic efficacy (kcat/Km) as the wild-type (WT) protein.12,15 These mutants remained susceptible to nirmatrelvir with no significant IC50 or Ki value shifts (<2-fold).12 Nevertheless, drug resistance to nirmatrelvir is anticipated, given the experience from the clinical use of HIV and HCV protease inhibitors.16,17 Several studies have been conducted to evolve or predict nirmatrelvir-resistant Mpro mutants.6−9,18−23 In parallel, we took an independent approach and systematically characterized drug-resistant Mpro mutants from naturally occurring SARS-CoV-2 variants using the Nsp5 sequences deposited in the GISAID database. [Figure: SARS-CoV-2 Mpro mutants identified from GISAID sequence analysis. (a) Residues with high mutation rates that were previously examined. None of the mutants showed significant drug resistance. (b) Residues located within 6 Å of the nirmatrelvir-binding site that were examined in this study. Figures were generated using Pymol with the X-ray crystal structure of nirmatrelvir in a complex with SARS-CoV-2 Mpro (PDB: 7SI9). Nirmatrelvir is colored magenta.] To identify drug-resistant mutants of Mpro, we focus on the active site residues that are located within 6 Å of the nirmatrelvir-binding site (PDB: 7SI9).2 In total, 12 residues were selected, including H41, M49, T135, N142, S144, H163, H164, M165, E166, H172, Q189, and Q192 (Figure 1b). We expect that mutations at these active site residues will have a direct impact on substrate binding and drug inhibition. To test this hypothesis, we analyzed the mutations of these 12 residues using the SARS-CoV-2 sequences deposited in GISAID,24 and the mutation frequency of each active site residue is plotted in Figure 2a. [Figure: SARS-CoV-2 Mpro mutants characterized in this study. (a) Mutations at 12 residues located at the nirmatrelvir-binding site. Sequence data were obtained from CoVsurver of the GISAID, developed by A*STAR Bioinformatics Institute (BII), Singapore. A total of 5 420 461 mutations of Nsp5 (Mpro) were obtained from the database as of July 7, 2022. Occurrence of total mutations for each amino acid residue is labeled in the center of each pie chart. The occurrences of specific mutations are labeled on the right of its affiliate pie chart. (b) Characterization of nirmatrelvir resistance against Mpro mutants by the thermal shift assay. The results are the average of duplicates.] We chose 102 mutants that cover all high-frequency mutations at these 12 residues based on the sequence analysis. Although the GISAID sequences are from clinical samples, not all mutants are likely from viable or infectious SARS-CoV-2 viruses, and the database might contain sequences from nonreplicating viruses or even sequencing errors (Figure 2a). As such, it is critical to experimentally characterize the Mpro mutations and identify the ones with potential clinical relevance. For this, 102 tag-free recombinant SARS-CoV-2 Mpro mutants with native N- and C-termini were expressed in

Read the complete text